Screener
Gilead Sciences GILD Product sales — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales | $7,627 | $7,054 | $14,574 | $13,668 |
| Royalty, contract and other revenues | 176 | 27 | 189 | 81 |
| Total revenues | 7,803 | 7,082 | 14,763 | 13,749 |
| Costs and expenses: | ||||
| Cost of goods sold | 1,579 | 1,501 | 3,023 | 3,041 |
| Research and development expenses | 1,764 | 1,491 | 3,136 | 2,870 |
| Acquired in-process research and development expenses | 11,183 | 61 | 11,290 | 315 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's product sales — total revenues?
- Gilead Sciences (GILD) reported product sales — total revenues of $7.63B in Q2 2026.
- How has Gilead Sciences's product sales — total revenues changed year-over-year?
- Gilead Sciences's product sales — total revenues increased by 8.1% year-over-year, from $7.05B to $7.63B.
- What is the long-term trend for Gilead Sciences's product sales — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's product sales — total revenues has grown at a 1.7% compound annual growth rate (CAGR), from $27.01B to $28.91B.
- What does product sales — total revenues mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products, excluding royalty, contract, and other non-product related income. It serves as the primary indicator of the company's commercial performance across its core therapeutic areas, including HIV, liver disease, and oncology. This figure reflects the market demand and pricing power of the company's portfolio of marketed therapies.
Ask your AI about Gilead Sciences's product sales — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude